Dupixent® (dupilumab) Late-Breaking Data from NOTUS : v

NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function,...

Related Keywords

United States , China , Massachusetts , Paris , France General , France , American , Regeneron Velocimmune , Surya Bhatt , Georged Yancopoulos , American Thoracic Society , International Conference , Division Of Pulmonary , Linkedin , Facebook , Nasdaq , Us Department Of Justice , Regeneron Genetics Center , Exchange Commission , University Of Alabama At Birmingham , Clinical Research Program , Regeneron Pharmaceuticals Inc , Dupilumab Development Program , European Union , Drug Administration , Euronext , Instagram , Trial Program , Thoracic Society , New England Journal , Critical Care Medicine , Respiratory Questionnaire , Evaluating Respiratory Symptoms , Priority Review , Chief Scientific Officer George , Nasal Polyposis , Prescribing Information , Regeneron Genetics , Forward Looking Statements , Regeneron Pharmaceuticals , Product Candidates ,